A phase 1 dose escalation study of the safety and pharmacokinetics of XL820 administered orally to subjects with solid tumors
Phase of Trial: Phase I
Latest Information Update: 02 Jun 2008
At a glance
- Drugs XL 820 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 02 Jun 2008 Status changed from in progress to completed according to clinicaltrials.gov.
- 04 Nov 2005 New trial record.